Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

IMPAX LABORATORIES INC (IPXL)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
06/20AMNEAL PHARMACEUTICALS : Announces Patent Litigation Settlement Agreement with A..
PR
06/14IMPAX LABORATORIES : LLC Announces Results of Tender Offer for 2.00% Convertible..
AQ
06/07AMNEAL PHARMACEUTICALS : Announces FDA Approval of Cyclophosphamide for Injectio..
AQ
06/06AMNEAL PHARMACEUTICALS : to Present at the Goldman Sachs 39th Annual Global Heal..
PR
06/05AMNEAL PHARMACEUTICALS : Impax Laboratories, LLC Announces Results of Tender Off..
PR
05/30AMNEAL PHARMACEUTICALS : Announces FDA Approval of Cyclophosphamide for Injectio..
PR
05/25AMNEAL PHARMACEUTICALS : Celebrates Combination by Ringing Opening Bell at New Y..
AQ
05/25AMNEAL PHARMACEUTICALS : Announces FDA Approval and Launch of Generic Welchol® C..
AQ
05/25IMPAX LABORATORIES : Administrative Law Judge Dismisses FTC Antitrust Complaint ..
AQ
05/23MABXIENCE : and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in th..
PR
More news
News from SeekingAlpha
05/01Premarket analyst action - healthcare 
04/27ANI Pharmaceuticals buying assets from Amneal, Impax 
04/24Looking For Action? S&P 1500 Most Volatile Stocks 
04/07Zuckerberg On Safari To Washington 
04/06Impax launches a generic version of Estrace cream 
Financials ($)
Sales 2018 1 923 M
EBIT 2018 500 M
Net income 2018 73,5 M
Debt 2018 2 238 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 4,01x
EV / Sales 2019 3,35x
Capitalization 5 466 M
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 21,8 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Robert A. Stewart Chief Executive Officer & Director
Chintu Patel Co-Chairman
Chirag K. Patel Co-Chairman
Andrew S. Boyer Executive Vice President-Commercial Operations
Bryan M. Reasons Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC9.91%5 466
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862